

A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome

D. Soldini^{1,†}, C. Montagna^{1,†}, P. Schüffler², V. Martin³, A. Georgis¹, T. Thiesler¹, A. Curioni-Fontecedro⁴, P. Went⁵, G. Bosshard¹, S. Dehler⁶, L. Mazzuchelli³ & M. Tinguely^{1*}

¹Institute of Surgical Pathology, University Hospital Zurich; ²Department of Computer Science, ETH Zurich, Zurich; ³Institute of Pathology, Locarno; ⁴Department of Oncology, University Hospital Zurich, Zurich; ⁵Institute of Pathology, Town Hospital Triemli, Zurich; ⁶Cancer Registry, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland

Received 29 March 2012; revised 22 May 2012; accepted 30 May 2012

Background: Aggressive mature B-cell non-Hodgkin's lymphomas (BCL) sharing features of Burkitt's lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) (intermediate BL/DLBCL) but deviating with respect to one or more characteristics are increasingly recognized. The limited knowledge about these biologically heterogeneous lymphomas hampers their assignment to a known entity, raising uncertainty about optimal treatment approaches. We therefore searched for discriminative, prognostic, and predictive factors for their better characterization.

Patients and methods: We analyzed 242 cytogenetically defined aggressive mature BCL for differential protein expression. Marker selection was based on recent gene-expression profile studies. Predictive models for diagnosis were established and validated by a different set of lymphomas.

Results: CSE1L- and inhibitor of DNA binding-3 (ID3)-overexpression was associated with the diagnosis of BL and signal transduction and transcription-3 (STAT3) with DLBCL ($P < 0.001$ for all markers). All three markers were associated with patient outcome in DLBCL. A new algorithm discriminating BL from DLBCL emerged, including the expression of CSE1L, STAT3, and MYC translocation. This 'new classifier' enabled the identification of patients with intermediate BL/DLBCL who benefited from intensive chemotherapy regimens.

Conclusion: The proposed algorithm, which is based on markers with reliable staining properties for routine diagnostics, represents a novel valid tool in separating BL from DLBCL. Most interestingly, it allows segregating intermediate BL/DLBCL into groups with different treatment requirements.

Key words: algorithm, BL, CSE1L, DLBCL, ID3, STAT3

Introduction

Accurate diagnosis of aggressive mature B-cell non-Hodgkin's lymphomas (BCL) is mandatory for the choice of an optimal treatment approach. In particular, the distinction of Burkitt's lymphoma (BL) from diffuse large B-cell lymphoma (DLBCL) entails important prognostic and therapeutic implications. Although both the entities are treated with curative intent, different regimens are applied: most patients with DLBCL are treated with rituximab plus cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin/vincristine and

prednisone (R-CHOP) chemotherapy, whereas a more intensive chemotherapy (e.g. Hyper-cyclophosphamide, vincristine, adriamycin/doxorubicin, dexamethasone) is applied for the treatment of BL.

The definition of these two entities incorporates clinical information, histomorphology, immunohistochemistry, as well as genetic alterations including BCL2, BCL6, and MYC translocations. With the advancement of molecular testing widely applicable to formalin-fixed, paraffin-embedded tissues, lymphomas with overlapping morphological and genetic features of both BL and DLBCL are increasingly recognized. In the current World Health Organization (WHO) classification, they are classified as 'B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL' (intermediate BL/DLBCL) [1]. The inherent complexity of this ill-defined group is reflected by their very heterogeneous nature,

*Correspondence to: Dr M. Tinguely, Institute of Surgical Pathology; University Hospital Zurich; Schmelzbergstrasse 12; CH-8091 Zurich, Switzerland. Tel: +41-44-255-47-24; Fax: +41-44-255-44-16; E-mail: marianne.tinguelykovarik@uzh.ch

[†]These authors contributed equally to this work.

comprising among others, double-hit lymphomas with MYC aberration, with a particularly negative prognostic impact [2, 3]. From the clinical point of view, a major issue regarding this aggressive group of lymphomas is the lack of an optimal treatment approach, and all attempts to define the borders of intermediate BL/DLBCL with known diagnostic markers, such as CD10, MUM1, Bcl2, Bcl6 protein expression or FISH for BCL2, BCL6 and MYC, remained unsatisfactory so far [1, 3, 4].

Therefore, the purpose of this study is to find additional diagnostic and predictive markers in order to further characterize aggressive mature BCL, with particular regard to intermediate BL/DLBCL. Based on the reported gene-expression profiling studies, which in the recent years were found to be an accurate method to distinguish BL from DLBCL, we analyzed the expression of three genes [chromosome segregation 1-like (CSE1L), inhibitor of DNA binding-3 (ID3), and signal transduction and transcription-3 (STAT3)] on a tissue micro array (TMA) [5, 6].

CSE1L is implicated in the nuclear-to-cytoplasmic trafficking of importin- α relevant for the nuclear transport of several proliferation-associated proteins, oncogenes, and tumor suppressor genes, such as p53. Although CSE1L was shown to be overexpressed in various carcinomas [7] and melanomas [8], few studies have reported high expression in high-grade B-NHL when compared with low-grade B-NHL [9], primary cutaneous B-cell lymphomas [10], or acute myeloid leukemias [11]. ID3 belongs to the inhibitor of DNA binding (ID) family of proteins which negatively regulate basic helix-loop-helix transcription factors known as E-proteins and control many aspects of lymphocyte proliferation, differentiation, and survival [12]. ID family proteins have been shown to be overexpressed in several solid tumors [13]; however, very little is known about the role of ID3 in human lymphomas [14, 15]. Finally, STAT3 belongs to the signal transduction and transcription (STAT) family of transcription factors and binds to interleukin (IL)-6 and IL-10 responsive elements. In cell culture assays, both cytokines and STAT3 were shown to be expressed by non-germinal-center-B-cell (non-GCB)-derived DLBCL cells. Moreover, a signature of STAT3 target genes typifies a subset of non-GCB DLBCL tumor cells with high STAT3 protein levels [16].

We investigated a cohort of 242 aggressive mature BCL for the expression of the mentioned markers CSE1L, ID3, and STAT3 on a TMA. Their diagnosis was initially established by morphology with the support of known immunophenotypical, and genetic markers. In a univariate analysis, all the three new markers were able to significantly discriminate BL from DLBCL, and their expression correlated with survival. Through computational analysis, we developed a new algorithm for aggressive mature BCL based on the combination of CSE1L and STAT3 expression with MYC rearrangement by FISH, which was superior in predicting the diagnosis of BL and DLBCL than previous marker combinations. Finally, the use of this algorithm appears to be of predictive value regarding the therapeutic response. Based on these data, we propose the use of these new markers as an additional diagnostic and predictive tool, which, however, needs to be analyzed prospectively on a larger number of cases before eventually being included in the routine diagnostic procedures.

patients and methods

patients and biopsy specimen selection

A total of 288 patients with aggressive mature BCL diagnosed from 1990 to 2009 at the Institute of Surgical Pathology, University Hospital Zurich as well as 10 BL cases derived from an affiliated hospital (Town Hospital Triemli) in Zurich were included in the study. Twenty-three additional BL or DLBCL cases collected during 2010 were used successively to validate the diagnostic algorithm. All lymphomas were reviewed independently by two pathologists (DS and MT) and diagnosed, according to the current WHO 2008 classification [1] as outlined in the supplementary data. DLBCL were further subclassified into GCB and non-GCB types, according to the Hans algorithm [17].

This study was in accordance with Swiss laws and approved by the official authorities of the ethical committee of the Canton Zurich (StV2-2007).

treatment protocol

According to the first-line chemotherapy used after the histological diagnosis, four therapeutic groups were established (for details, see supplementary data). The 'first' group (89 patients) consisted of 'CHOP-like' regimens, the 'second' group (16 patients) consisted of 'intensive' regimens, the 'third' group (6 patients) comprised vincristine, adriamycin/doxorubicin, cyclophosphamide, etoposide, and prednisone (VACOP), and the 'fourth' group (6 patients) comprised 'low-intensity' regimens chlorambucil and prednisolone [18]. Each group was further subclassified according to the use of rituximab.

immunohistochemistry

Based on gene-expression profiling [5, 6], we searched for reported genes significantly overexpressed in either BL or DLBCL and selected the commercially available antibodies specific for CSE1L, ID3, and STAT3 which showed the best staining performance and reproducibility in normal and neoplastic lymphatic tissues. For antibodies used and their evaluation see supplementary Table S1, available at *Annals of Oncology* online. Immunohistochemistry on 2.5- μ m-thick TMA sections was carried out using a Ventana ES instrument (Roche's Ventana Medical Systems, Baar, Switzerland) according to the standard protocols.

western blotting

Protein extracts from human BL-derived Raji cells were subjected to Western blotting analysis. An anti- β -actin (mouse monoclonal, clone AC-15, code A5441, Sigma-Aldrich, Hamburg, Germany) antibody was used as a control for protein loading. (supplementary Figure S1, available at *Annals of Oncology* online).

fluorescence *in situ* hybridization (FISH)

FISH analysis was carried out as previously described [19, 20] and evaluated by a cytogenetist (VM) who was blinded to the clinical evaluation and remaining results. See supplementary Table S2, available at *Annals of Oncology* online for probes used.

diagnostic algorithm for decision trees and their validation

Computational analysis of the protein expression data lead to predictive models for the diagnosis of interest. We chose binary decision trees, as these easily handle missing values of the predictor variables and have already been used in this context [17, 21]. Several binary decision trees for the classification of BL versus DLBCL were trained with different datasets composed of protein expression and FISH results as predictor variables. The

Table 1. Immunohistochemical and genetic characteristics of all cases

	All cases <i>n</i> (%)	BL <i>n</i> (%)	DLBCL <i>n</i> (%)	Intermediate DLBCL/BL <i>n</i> (%)	<i>P</i> value
Total	242 (100.0)	22 (9.1)	193 (79.8)	27 (11.2)	
Age at diagnosis					<0.001
Median	60.5	37.5	63	54	
Mean	58.1	38.6	61.2	51.3	
<60 years	118 (45.9)	18 (81.8)	83 (43.0)	17 (63.0)	
≥60 years	124 (54.1)	4 (18.2)	110 (57.0)	10 (37.0)	
Gender					0.006
Female	107 (44.2)	3 (13.6)	90 (46.6)	14 (51.9)	
Male	135 (55.8)	19 (86.4)	103 (53.4)	13 (48.1)	
HIV					0.135
Positive	22 (9.1)	3 (13.6)	16 (8.3)	3 (11.1)	
Negative	8 (3.3)	4 (18.2)	4 (2.1)	0 (0.0)	
Not known	212 (87.6)	15 (68.2)	173 (89.6)	24 (88.9)	
CD20 expression					1
Positive	242 (100.0)	22 (100.0)	193 (100.0)	27 (100.0)	
Negative	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
Bcl-1 expression					1
Positive	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
Negative	242 (100.0)	22 (100.0)	193 (100.0)	27 (100.0)	
CD5 expression					0.58
Positive	10 (4.1)	0 (0.0)	10 (5.2)	0 (0.0)	
Negative	232 (95.9)	22 (100.0)	183 (94.8)	27 (100.0)	
CD10 expression					<0.001
Positive	99 (40.9)	22 (100)	57 (29.5)	20 (74.1)	
Negative	143 (59.1)	0 (0.0)	136 (70.5)	7 (25.9)	
MUM1 expression					0.403
Positive	58 (24.0)	4 (18.2)	50 (25.9)	4 (14.8)	
Negative	184 (76.0)	18 (81.8)	143 (74.1)	23 (85.2)	
Germinal-center B-cell (GCB) or non-GCB signature					<0.001
GCB	122 (50.4)	22 (100)	78 (40.4)	22 (81.5)	
non-GCB	120 (49.6)	0 (0.0)	115 (59.6)	5 (18.5)	
Mib-1 score					<0.001
<90%	203 (83.9)	0 (0.0)	189 (97.9)	14 (51.9)	
At least 90%	39 (16.1)	22 (100)	4 (2.1)	13 (48.1)	
MYC breakpoint					<0.001
Translocation	48 (25.9)	22 (100)	8 (5.8)	18 (69.2)	
No translocation	137 (74.1)	0 (0.0)	129 (94.2)	8 (30.8)	
Bcl-2 expression					0.003
Positive	83 (34.3)	1* (4.5)	71 (36.8)	11 (40.7)	
Negative	159 (65.7)	21 (95.5)	122 (63.2)	16 (59.3)	
IGH-BCL2 fusion					0.078
Fusion	31 (14.5)	0 (0.0)	25 (14.5)	6 (24.0)	
No fusion	183 (85.5)	17 (100.0)	147 (85.5)	19 (76.0)	
Bcl-6 expression					<0.001
Positive	100 (41.5)	15 (71.4)	67 (34.7)	18 (66.7)	
Negative	141 (58.5)	6 (28.6)	126 (65.3)	9 (33.3)	
BCL6 breakpoint					0.017
Translocation	41 (32.3)	0 (0.0)	33 (35.1)	8 (40.0)	
No translocation	86 (67.7)	13 (100.0)	61 (64.9)	12 (60.0)	
Number of translocations					<0.001**
MYC alone	38 (36.9)	22 (100.0)	8 (12.9)	8 (42.1)	
MYC and BCL2	3 (2.9)	0 (0.0)	0 (0.0)	3 (15.8)	
MYC and BCL6	4 (3.9)	0 (0.0)	0 (0.0)	4 (21.1)	
MYC, BCL2, and BCL6	3 (2.9)	0 (0.0)	0 (0.0)	3 (15.8)	
BCL2 and BCL6	4 (3.9)	0 (0.0)	4 (6.5)	0 (0.0)	

Continued

Table 1. Continued

	All cases <i>n</i> (%)	BL <i>n</i> (%)	DLBCL <i>n</i> (%)	Intermediate DLBCL/BL <i>n</i> (%)	<i>P</i> value
BCL6 alone	30 (29.1)	0 (0.0)	29 (46.8)	1 (5.3)	0.02
BCL2 alone	21 (20.4)	0 (0.0)	21 (33.9)	0 (0.0)	
EBER (<i>in situ</i>)					
Positive	17 (7.1)	5 (23.8)	11 (5.8)	1 (3.7)	
Negative	222 (92.9)	16 (76.2)	180 (94.2)	26 (96.3)	

Percentages were calculated on the basis of the number of evaluable cases (or on the basis of the total number of cases showing at least one translocation). Percentages may not total 100 because of rounding.

P values were calculated using Fisher's exact test (or the chi-square test, for **) and refer to differences between the BL, DLBCL and intermediate BL/DLBCL cases.

The expression of CD20, CyclinD1, CD5, CD10, MUM1, Mib-1, Bcl-2, and Bcl-6 was determined by immunohistochemical analysis.

The MYC and BCL6 breakpoints and the IGH-BCL2 fusions were analyzed by interphase fluorescence *in situ* hybridization (FISH).

*Weak intensity (Bcl2 expression).

BL, Burkitt's lymphoma; DLBCL, diffuse large B-cell lymphoma.

Table 2. Clinical characteristics of the patients

	All cases <i>n</i> (%)	BL <i>n</i> (%)	DLBCL <i>n</i> (%)	Intermediate DLBCL/BL <i>n</i> (%)
Total	220	18	178	24
Age at diagnosis				
Median	63	41	66	56
Mean	59.6	41.9	62.3	53.3
<18 years	4	2	2	0
18 years to <60 years	93	12	66	15
≥60 years	123	4	110	9
Gender				
Female	96 (43.6)	3 (16.6)	81 (45.5)	12 (50.0)
Male	124 (56.4)	15 (83.4)	97 (54.5)	12 (50.0)
Localization				
Nodal only	107 (48.6)	10 (55.5)	84 (47.2)	13 (54.2)
Extranodal only	75 (34.1)	7 (38.9)	63 (35.4)	5 (20.8)
Nodal and extranodal	38 (17.3)	1 (5.6)	31 (17.4)	6 (25.0)
Therapy				
CHOP-like regimen	89 (74.2)	5 (31.2)	75 (84.3)	9 (60.0)
Intensive regimen	16 (13.3)	9 (56.2)	2 (2.2)	5 (33.3)
VACOP	6 (5.0)	2 (12.5)	4 (4.5)	0 (0.0)
Low-intensity regimen	6 (5.0)	0 (0.0)	6 (6.7)	0 (0.0)
No treatment	3 (2.5)	0 (0.0)	2 (2.2)	1 (6.7)
Rituximab				
No	62 (48.1)	9 (52.9)	44 (45.8)	9 (56.2)
Yes	67 (51.9)	8 (47.1)	52 (54.2)	7 (43.7)
Radiotherapy				
No	94 (69.6)	13 (76.5)	70 (68.6)	11 (68.7)
Yes	41 (30.4)	4 (23.5)	32 (31.4)	5 (31.2)
Response to treatment				
Complete remission	65 (29.6)	10 (55.6)	49 (27.5)	6 (25.0)
Recurrence	60 (27.2)	4 (22.2)	47 (26.4)	9 (37.5)
Death without disease-free interval	51 (23.2)	2 (11.1)	42 (23.6)	7 (29.1)
Loss of follow-up	44 (20.0)	2 (11.1)	40 (22.5)	2 (8.4)

Percentages were calculated on the basis of the number of cases with available information. The omission of cases without clinical information explains the difference in 'age at diagnosis' and 'gender' existing between Tables 1 and 2. Percentages may not reach a total of 100 because of rounding.

BL, Burkitt's lymphoma; DLBCL, diffuse large B-cell lymphoma.




Figure 1. Results of immunohistochemical markers. 'CSE1L' in reactive lymphoid tissue at (A) low (20×) and (B) high power (40×) magnification with predominant, cytoplasmic reactivity in germinal-center dark cells and less strong in the light zone, but not in mantle zone cells or extra-follicular area. Examples (40×) of both (C) Burkitt's lymphoma (BL) and (D) diffuse large B-cell lymphoma (DLBCL). Inhibitor of DNA binding-3 (ID3) in reactive lymphoid tissue at (E) low and (F) high power magnification with nuclear reactivity in both germinal-center and mantle zone cells. Lymphoma examples of both (G) BL and (H) DLBCL. Signal transduction and transcription-3 (STAT3) in reactive lymphoid tissue at (I) low and (J) high power with only few cells with cytoplasmic reactivity, mainly in the extra-follicular area. Examples of samples of both (K) BL and (L) DLBCL.

resulting decision trees were compared by their misclassification error of 100-fold bootstrapped cross-validation. The validation of the decision trees was carried out using a separate group of 23 new lymphomas, for which the same immunohistochemical and FISH analysis were carried out as in the initial cohort. This validation cohort was evaluated as before by a cytogeneticist (VM) and an assessor (CM) who were blinded to the diagnosis.

clinical data and survival analysis

The following patient characteristics were collected: age at diagnosis, gender, lymphoma site, and therapeutic strategy. The response to treatment and the occurrence of relapse or death was recorded. The Kaplan-Meier method was used to estimate overall (OS) and progression-free survival (PFS) (see supplementary data, available at *Annals of Oncology* online for definition).

The log-rank test, stratified by the diagnostic group, was used to compare the survival distributions. The differences between the strata were tested with the chi-square test.

results

patients and diagnosis

Out of the 288 biopsies, 242 fulfilled the requirement for further analysis with a minimum of 30% of tumor cells on the

tissue core. Of these, 22 were classified as BL, 193 as DLBCL, and 27 as intermediate BL/DLBCL. Clinical data were available for 220 patients (18 BL, 178 DLBCL, and 24 intermediate BL/DLBCL). The mean follow-up was 5.2 years for BL patients, 4.3 years for DLBCL patients, and 3.3 years for intermediate BL/DLBCL patients. A summary of the characteristics of tumors and patients is presented in Tables 1 and 2.

expression of CSE1L, ID3, and STAT3 in normal lymphatic tissues and in human BL-derived raji cells

The specificity of these antibodies was confirmed in a Western blot analysis (supplementary Figure S1, available at *Annals of Oncology* online).

In non-neoplastic tissue, CSE1L and ID3 were predominantly expressed in GCB cells, whereas STAT3 was expressed in cells of the inter-follicular area (Figure 1).

expression of CSE1L, ID3, and STAT3 in BL, DLBCL and intermediate BL/DLBCL

A univariate analysis revealed a statistically significant differential expression of CSE1L, ID3, and STAT3 in BL




Figure 2. Decision trees trained to predict the diagnosis of either Burkitt's lymphoma (BL) or diffuse large B-cell lymphoma (DLBCL) with different sets of markers and FISH results ($n = 248$). The 'conventional classifier without FISH data' resulted when all conventional markers (CD10, MUM1, Bcl-2, and Bcl-6) were submitted to the algorithm. When the FISH data (BCL2, BCL6, and MYC translocations) were in addition applied, the algorithm chose the expression of CD10 and the data of FISH for MYC to build the 'conventional classifier with FISH data'. When the expression of new markers CSE1L, inhibitor of DNA binding-3 (ID3), and signal transduction and transcription-3 (STAT3) as well as conventional markers were submitted to the binary decision tree, only two new markers CSE1L and STAT3 were selected to build an algorithm, called 'classifier without FISH data'. Finally, the decision tree with the highest performance resulted when all (conventional and new) markers in addition to FISH data were applied. This 'new classifier' was composed of the data of the expression of CSE1L and STAT3 and of the FISH data for MYC.

versus DLBCL (Figure 1). CSE1L and ID3 were both found to be more frequently expressed in BL than in DLBCL (for both $P < 0.001$). STAT3, instead, was more frequently expressed in DLBCL ($P < 0.001$), in particular more often in the non-GCB than in the GCB subgroup ($P < 0.001$). For summary, see supplementary Table S3, available at *Annals of Oncology* online.

survival analysis and correlation with marker expression

For 220 patients, follow-up was available. Twenty-nine percent of them relapsed and 23% of the patients had no disease-free interval (supplementary Table S4, available at *Annals of Oncology* online).

Overall, univariate survival analysis showed that ID3-positive patients had significantly longer OS and PFS than ID3-negative patients ($P = 0.020$, with 5-year OS of 63.5% versus 44.7%; $P = 0.033$, with 5-year PFS of 56.3% versus 36.8%), and CSE1L expression was associated with longer PFS ($P = 0.044$, with 5-year PFS of 61.0% versus 40.1%). Finally, considering only the group of DLBCL, the expression of STAT3 was associated with longer OS ($P = 0.052$, with 5-year OS of 53.0% versus 38.4%) and PFS ($P = 0.023$; with 5-year PFS of 44.7% versus 30.7%). Neither OS ($P = 0.920$) nor PFS ($P = 0.796$) differed in GCB versus non-GCB assessed by Hans classifier.

diagnostic classifiers for BL and DLBCL

In order to evaluate whether the 'combined' expression of CSE1L, ID3, and STAT3 enhances diagnostic precision, we made use of binary decision trees to predict diagnosis. As this computational approach is based on a binary system, the group of insufficiently defined intermediate BL/DLBCL was omitted, and decision trees were trained to predict the diagnosis of either

BL or DLBCL. Different combination sets with the expression of new markers, CSE1L, ID3, and STAT3, of conventional markers (CD10, MUM1, Bcl-2, and Bcl-6), as well as FISH results for BCL2, BCL6 and MYC translocations were introduced into the algorithm, which in turn selected the markers to build the best decision trees, also called classifiers (Figure 2).

From all different combinations of datasets applied, the algorithm selected STAT3 and CSE1L expression, as well as MYC translocation to build the decision tree with the highest performance. This decision tree, which we called 'new classifier', showed the lowest misclassification error of 8.7% [standard deviation (SD) = 5.6% in 100-fold bootstrapped cross-validation with a random level of 50.0% as balanced error] (see Figure 3 for all different classifiers).

validation of the new classifier

The validation of a predictive decision tree must be carried out using a different set of cases than the ones used for their training, and consists in the comparison of the original diagnosis with the one predicted by the decision tree. For this purpose, 23 additional aggressive mature BCL cases (5 BL and 18 DLBCL) recently diagnosed at the University Hospital Zurich were employed. The 'new classifier' predicted a correct diagnosis in all BL and DLBCL cases, with a sensitivity and specificity of 100% (see supplementary Table S5, available at *Annals of Oncology* online).

impact of the new classifier on diagnosis and prognosis, in particular for the intermediate BL/DLBCL group of lymphomas

We first added the whole cohort with all three lymphoma types including intermediate BL/DLBCLs to the training set, as the




Figure 3. Performance of the decision trees. Performance of the decision trees is based on the misclassification error (0%–100%). The misclassification error is lowered by adding the new markers to the conventional markers as indicated in Figure 2. This holds true for strategies including FISH or not (A = conventional classifier without FISH data, B = classifier without FISH data, C = conventional classifier with FISH, and D = new classifier). Statistical significance is given for two of the three markers: P values from left to right for the differences between the two adjacent markers: $P = 2.8 \times 10^{-20}$ (difference A to B), $P = 4.4 \times 10^{-10}$ (difference B to C), $P = 0.12$ (difference C to D) (calculated with Welch's two sample t -test).

latter were excluded from the initial set. Over the whole cohort, six DLBCL cases were reclassified as predicted BL (pBL) and two BL cases as predicted DLBCL (pDLBCL). By running the 'new classifier' over the intermediate BL/DLBCL group only, 13/27 lymphomas were predicted as BL (pBL) and 14/27 as DLBCL (pDLBCL). Interestingly, none of the pBL cases showed MUM1 expression, in contrast to four positive (28.6%) pDLBCL cases. GCB phenotype was present in 12/13 (92.3%) pBL cases and 10/14 (71.4%) pDLBCL cases. All pBL carried a MYC translocation (in contrast to 6/14 pDLBCL) and seven of them presented with a simple karyotype (only 1/14 pDLBCL). Both the groups presented five cases with triple or double hits each. Finally, STAT3 expression was more frequent in the pDLBCL (71.4%) than in the pBL (7.7%) group.

We next analyzed the influence of the new classifier on prognosis. We compared OS and PFS of predicted groups receiving an intensive therapy versus CHOP-like therapy with or without rituximab, as these two therapeutic groups represented >90% of all therapeutic approaches in our cohort.

Regarding all lymphoma subtypes, the 'new classifier' identified patients with pBL showing a significantly longer cumulative OS and PFS when treated with intensive therapy than pBL treated with CHOP-like therapy, with or without rituximab ($P = 0.015$ and $P = 0.007$, respectively) (Figure 4A). When the predicted diagnoses were compared with the initial ones, the prognosis for 4/6 pBL patients initially diagnosed as DLBCL was dismal (no disease-free interval and disease-related death occurring 0.5, 1.2, 1.8, and 13.9 months after diagnosis). The therapeutic approach was known in one case (R-CHOP, 1.2 months survival). The remaining 2 pBL recurred after 22.56 and 77.5 months, respectively, and were treated with R-CHOP chemotherapy. The two cases reclassified as pDLBCL, originally diagnosed as BL, had an indolent course (recurrence after 81 months, no recurrence after 192 months). Of note, reclassified lymphomas presented with features otherwise indistinguishable from the rest of the original diagnostic group.

Finally, the predictive value of the 'new classifier' was also evident when applied to the intermediate BL/DLBCL. In particular, the 'new classifier' was able to predict a significantly longer OS and PFS in pBL treated with intensive regimen compared with pBL treated with CHOP-like regimens, with or without rituximab ($P = 0.040$ for both OS and PFS, clinical data available for 14 patients,) (Figure 4B).

discussion

In this report, we present three immunohistochemical markers (CSE1, ID3, and STAT3) differentially expressed in BL and DLBCL as well as a new decision tree, comprising the protein expression of CSE1, STAT3, and MYC translocation, which enables improved segregation of BL from DLBCL, and of intermediate BL/DLBCL into two different prognostic groups. CSE1L and ID3 were more frequently expressed in BL. In contrast, STAT3 expression was associated with DLBCL, especially the non-GCB subgroup. As expected, our findings correlate with the increased transcription levels previously reported in gene-expression studies [5, 6]. Moreover, we could confirm previous reports of STAT3 overexpression in non-GCB-type DLBCL, both in a small series of primary lymphomas and in cell lines [16, 22]. Increased CSE1L expression has also been reported in highly proliferating lymphomas, including DLBCL, and a gain of the gene locus was reported in primary cutaneous B-cell lymphomas. In the case of ID3, a very limited data are available about its expression and potential role in lymphomas [9, 10, 14, 15].

Although the entity of BL is well characterized, its distinction from DLBCL is not always unequivocal. In order to improve the diagnostic accuracy of these entities, predictive models were trained with different predictor sets (traditional and new markers, FISH data) and cross-validated in 100-fold bootstrapping, with the diagnosis of BL or DLBCL, representing the prediction targets. The algorithm with highest discriminative capacity comprised STAT3, CSE1L, and MYC translocation. This algorithm, called 'new classifier', demonstrates the lowest misclassification error for the distinction of BL versus DLBCL when applied to the whole cohort (Figures 2 and 3). The validation of the proposed predictive model on 23 recently diagnosed aggressive mature




Figure 4. Relationship of the treatment of predicted Burkitt's lymphoma (BL) and overall survival (OS). OS of predicted BL treated with intensive therapy (red; (A) $n = 12$; (B) $n = 3$) versus CHOP-like regimens (black; (A) $n = 13$; (B) $n = 6$), when all cases are considered (A) and when only intermediate BL/DLBCLs are considered (B).

BCL on the whole tissue sections displays a high agreement with the results obtained on the TMA. Of note, the classifier appears superior in instances where FISH is unavailable (Figure 3).

Most interestingly, the 'new classifier' emerged as the only algorithm with the predictive value for all lymphomas. Notably, when the 'new classifier' was applied to the whole cohort including the intermediate BL/DLBCL group, it predicted a more favorable outcome in patients identified as pBL if treated with intensive therapy rather than the CHOP-like regimen (Figure 4). The 'new classifier' presented seems therefore to be very promising in identifying patients who might benefit from high-dose chemotherapy regimens. This stratification into groups of patients responding to intensive chemotherapy appears particularly meaningful for two reasons. First, no standardized treatment recommendations exist for patients diagnosed as intermediate BL/DBCL. In particular, recent studies showed a certain benefit for BL-oriented therapies, but not for DLBCL-oriented R-CHOP regimens, in patients with double-hit lymphomas with concurrent BCL2 and MYC translocations [23, 24]. However, as the group of intermediate BL/DLBCLs includes also cases which might not require an intensive therapy [24], the identification of pDLBCL cases will allow a more individualized therapeutic approach even in patients with lymphomas with biological overlap. Second, as shown by the few DLBCLs identified as pBLs, some cases presenting with characteristic features of DLBCL carry a very aggressive course and might require an intensive therapy. Their identification was not possible with conventional methods, but with the proposed 'new classifier'. Hence, the additional, predictive approach to lymphomas by the 'new classifier' might open new horizons in treatment planning and allows affronting biologically overlapping lymphomas in an alternative than the mere cell-of-origin-based way.

The validity of our study population is evidenced by the significantly better OS and PFS of patients with an initial diagnosis of BL than those with DLBCL, whereas patients diagnosed as intermediate BL/DLBCL showed the poorest outcome as reported in the literature (data not shown) [23, 24].

Recent studies have suggested a potential role for CSE1L, STAT3, and ID3 in oncology drug development. CSE1L overexpression was shown to enhance apoptosis induced by certain chemotherapeutic drugs [25, 26]. For ID3, a number of studies in solid tumors suggest a role as a putative target [27–29]. STAT3 has been proposed as a putative therapeutic target, either indirectly by proteasome inhibitors (e.g. bortezomib) and histone deacetylase inhibitors, or as a direct molecular target of drugs currently under development [30, 31].

In summary, we present a new algorithm, which beyond its diagnostic potency, bears predictive potential to treatment response allowing tailored therapeutic approaches, in particular for patients with intermediate BL/DLBCLs. Moreover, the markers presented in this article represent easily detectable molecules. Altogether, we believe that these data merit confirmation by prospective studies on larger cohorts.

acknowledgements

We are grateful to Silvia Behnke and Martina Storz for excellent technical assistance, as well as to the team of the cancer registry for invaluable support. We thank E. Haralambieva and Th. Fuchs for fruitful discussions, and J. Buhmann for pleasant collaboration and support.

funding

The work was in part supported by grants from the Helmut Horten Stiftung (DS), the San Salvatore Foundation (DS),

Fondazione Ticinese per la Ricerca sul Cancro (DS), and Krebsliga Zurich (MT).

disclosure

The authors have declared no conflicts of interest.

references

1. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. In World Health Organization Classification of Tumours, 4th Edition. Lyon: IARC 2008.
2. Aukema SM, Siebert R, Schuurung E et al. Double-hit B-cell lymphomas. *Blood* 2011; 117: 2319–2331.
3. Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. *Hematology (Am Soc Hematol Educ Program)* 2011; 2011: 506–514.
4. Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. *J Clin Oncol* 2011; 29: 1835–1843.
5. Hummel M, Bentink S, Berger H et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. *N Engl J Med* 2006; 354: 2419–2430.
6. Dave SS, Fu K, Wright GW et al. Molecular diagnosis of Burkitt's lymphoma. *N Engl J Med* 2006; 354: 2431–2442.
7. Brinkmann U. CAS, the human homologue of the yeast chromosome-segregation gene CSE1, in proliferation, apoptosis, and cancer. *Am J Hum Genet* 1998; 62: 509–513.
8. Boni R, Wellmann A, Man YG et al. Expression of the proliferation and apoptosis-associated CAS protein in benign and malignant cutaneous melanocytic lesions. *Am J Dermatopathol* 1999; 21: 125–128.
9. Wellmann A, Krenacs L, Fest T et al. Localization of the cell proliferation and apoptosis-associated CAS protein in lymphoid neoplasms. *Am J Pathol* 1997; 150: 25–30.
10. Mao X, Lillington D, Child F et al. Comparative genomic hybridization analysis of primary cutaneous B-cell lymphomas: identification of common genomic alterations in disease pathogenesis. *Genes Chromosomes Cancer* 2002; 35: 144–155.
11. Casas S, Ollila J, Avenir A et al. Changes in apoptosis-related pathways in acute myelocytic leukemia. *Cancer Genet Cytogenet* 2003; 146: 89–101.
12. Rivera R, Murre C. The regulation and function of the Id proteins in lymphocyte development. *Oncogene* 2001; 20: 8308–8316.
13. Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. *Oncogene* 2001; 20: 8326–8333.
14. Li XJ, Hata K, Mizuguchi J. Engagement of membrane immunoglobulin enhances Id3 promoter activity in WEHI-231 B lymphoma cells. *Acta Pharmacol Sin* 2005; 26: 486–491.
15. Li J, Maruyama T, Zhang P et al. Mutation of inhibitory helix–loop–helix protein Id3 causes γ delta T-cell lymphoma in mice. *Blood* 2010; 116: 5615–5621.
16. Lam LT, Wright G, Davis RE et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-(κ)B pathways in subtypes of diffuse large B-cell lymphoma. *Blood* 2008; 111: 3701–3713.
17. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood* 2004; 103: 275–282.
18. Muwakkit SA, Razzouk BI, Shabb NS et al. Clinical presentation and treatment outcome of children with Burkitt lymphoma in Lebanon: a single institution's experience. *J Pediatr Hematol Oncol* 2004; 26: 749–753.
19. Tibiletti MG, Martin V, Bernasconi B et al. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. *Hum Pathol* 2009; 40: 645–652.
20. Ventura RA, Martin-Subero JL, Jones M et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. *J Mol Diagn* 2006; 8: 141–151.
21. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. 2nd Edition. New York: Springer.
22. Ding BB, Yu JJ, Yu RY et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. *Blood* 2008; 111: 1515–1523.
23. Snuderl M, Kolman OK, Chen YB et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. *Am J Surg Pathol* 2010; 34: 327–340.
24. Savage KJ, Johnson NA, Ben-Neriah S et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. *Blood* 2009; 114: 3533–3537.
25. Liao CF, Luo SF, Shen TY et al. CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs. *BMB Rep* 2008; 41: 210–216.
26. Tai CJ, Hsu CH, Shen SC et al. Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis. *J Exp Clin Cancer Res* 2010; 29: 110.
27. Mern DS, Hoppe-Seyler K, Hoppe-Seyler F et al. Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells. *Breast Cancer Res Treat* 2010; 124: 623–633.
28. Kamalian L, Forootan SS, Bao ZZ et al. Inhibition of tumorigenicity of small cell lung cancer cells by suppressing Id3 expression. *Int J Oncol* 2010; 37: 595–603.
29. Shuno Y, Tsuno NH, Okaji Y et al. Id1/Id3 knockdown inhibits metastatic potential of pancreatic cancer. *J Surg Res* 2010; 161: 76–82.
30. Fletcher S, Drewry JA, Shahani VM et al. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. *Biochem Cell Biol* 2009; 87: 825–833.
31. Borghouts C, Tittmann H, Delis N et al. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death. *Mol Cancer Res* 2010; 8: 539–553.